...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Thoughts on ZCC

Fouremm,

 

Very good point that DM can only do $1.5 usd per share PP, He should be directly asked that question why he can't get a much better share price valuation when his peers are beong sold at almost 7 times what he is selling PP at , Why can't ENSANA helpout this valuation problem or another outfit...... DM must go if he can't fix the valuations for both RVX and ZEnith, He has had enough time to figure it out and he has failed IMO ,  I can tell you the minute he is replaced i will be adding to my position of both companies 

Share
New Message
Please login to post a reply